Last reviewed · How we verify
SCT510
The specific mechanism of action for SCT510 is not publicly disclosed.
At a glance
| Generic name | SCT510 |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As the mechanism of action has not been detailed in public sources, it is unclear how SCT510 interacts with biological processes to achieve its therapeutic effects.
Approved indications
Common side effects
Key clinical trials
- SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (PHASE2, PHASE3)
- PK and Safety of SCT510 (PHASE1)
- To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT510 CI brief — competitive landscape report
- SCT510 updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI